Eli Lilly and Company (NYSE:LLY) Shares Sold by FDx Advisors Inc.

FDx Advisors Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 94.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 520 shares of the company’s stock after selling 8,664 shares during the quarter. FDx Advisors Inc.’s holdings in Eli Lilly and Company were worth $471,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of LLY. AMJ Financial Wealth Management bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $201,000. Providence First Trust Co bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $274,000. Aveo Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 8.2% in the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares during the last quarter. Gryphon Financial Partners LLC lifted its holdings in shares of Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares during the last quarter. Finally, Bogart Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 61.5% in the 4th quarter. Bogart Wealth LLC now owns 289 shares of the company’s stock worth $168,000 after purchasing an additional 110 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 75,510 shares of Eli Lilly and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the transaction, the insider now directly owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 876,900 shares of company stock worth $788,605,032. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $946.31 on Thursday. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The stock has a fifty day moving average price of $895.96 and a 200 day moving average price of $826.05. The stock has a market cap of $899.38 billion, a price-to-earnings ratio of 139.37, a PEG ratio of 2.91 and a beta of 0.41. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, August 19th. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.